Nov 19 2008
Acrongenomics, Inc. (OTCBB:AGNM) are pleased to announce that the restructuring of our relationship with Molecular Vision Limited (an Imperial College London spin-out company) as first announced on August 21, 2008, is now fully and finally completed.
As a result, Acrongenomics becomes the largest single shareholder in Molecular Vision, with an approximately 28% ownership. Thus, Acrongenomics acquires a significant stake in the Molecular Vision technology and its current patents. Until August 19, 2008, we had been operating pursuant to a Development Agreement originally dated May 23, 2006 and amended thereafter, whereby we funded with approximately US $4 million the development of the Point of Care device of Molecular Vision in specific medical diagnostics fields, in return for a license to commercialize and sell that device. Under formal agreements dated November 13, 2008, we and Molecular Vision terminated the Development Agreement.
In addition to and regardless of its shareholding in Molecular Vision, Acrongenomics is entitled to two separate forms of royalties: i) 5% on indirect license fee sales (i.e. sales from any other company) and 0.5% on direct product sales received by Molecular Vision for products based on Molecular Vision’s current suite of patents regarding any and all medical diagnostics; and ii) 3% on indirect license fee sales and 0.3% on direct product sales received by Molecular Vision for products in all other fields of application based on Molecular Vision’s current suite of patents. Taking into account the potential of the Molecular Vision technology, this clearly aims at creating a substantial stream of revenues for our company over the next 20 years.
Further to the above and as part of the transaction, Acrongenomics will be entitled to appoint a director to the board of Molecular Vision. We are pleased to announce that we have designated Dr. Emmanuel (Manos) Topoglidis as our representative on the Molecular Vision board. Dr. Topoglidis, a graduate of Imperial College London, is our Chief Technology Officer, a member of our Board of Directors and a member of our Scientific Advisory Board.
“It is a great pleasure for me personally to formally announce the final completion of a major deal and the opening of a new era in our company history”, said Dr. Evan Manolis, Chairman of the Board of Directors of Acrongenomics. “All of us involved in the new team have worked hard and made heavy efforts over the last months. Our company has indeed turned the page and opened a new chapter in its history, and the completion of this deal demonstrates both our strong capabilities and our great potential. A big “thank you” to all in our team”.